Cargando…

Successful treatment with DCF chemotherapy and radiotherapy for primary squamous cell carcinoma of the prostate

INTRODUCTION: Primary squamous cell carcinoma of the prostate is an extremely rare tumor with poor prognosis. Squamous cell carcinoma of the prostate is estimated to comprise less than 1% of all prostate carcinomas. We report herein a case with clinical response to docetaxel, cisplatin, and 5‐fluoro...

Descripción completa

Detalles Bibliográficos
Autores principales: Atagi, Kaya, Fukuhara, Hideo, Ishiguro, Motoyoshi, Osakabe, Hiroto, Satoshi, Fukata, Tamura, Kenji, Karashima, Takashi, Inoue, Keiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560450/
https://www.ncbi.nlm.nih.gov/pubmed/34755073
http://dx.doi.org/10.1002/iju5.12365
Descripción
Sumario:INTRODUCTION: Primary squamous cell carcinoma of the prostate is an extremely rare tumor with poor prognosis. Squamous cell carcinoma of the prostate is estimated to comprise less than 1% of all prostate carcinomas. We report herein a case with clinical response to docetaxel, cisplatin, and 5‐fluorouracil chemotherapy with radiotherapy, in a patient with metastatic squamous cell carcinoma of the prostate. CASE PRESENTATION: A 74‐year‐old man consulted with frequent urination. The prostate‐specific antigen level was 1.62 ng/mL. Multiparametric magnetic resonance imaging showed prostate imaging and reporting and data system category 5 for the whole prostate and biopsy was performed. The pathological diagnosis was pure squamous cell carcinoma of the prostate. fluorodeoxyglucose positron emission tomography showed fluorodeoxyglucose accumulation in the whole prostate and multiple pelvic lymph nodes. Four cycles of docetaxel, cisplatin, and 5‐fluorouracil regimen were administrated along with radiotherapy. The patient showed a marked response with no major adverse events. CONCLUSION: The present case suggests the potential of docetaxel, cisplatin, and 5‐fluorouracil chemotherapy with radiotherapy for squamous cell carcinoma of the prostate.